The Prevalence of Factor XII Deficiency in 103 Orally Anticoagulated Outpatients Suffering from Recurrent Venous and/or Arterial Thromboembolism

 

PDF Download Buy Article Permissions and Reprints

Summary

One hundred and three patients suffering from recurrent venous thrombosis, recurrent arterial thromboembolism and/or recurrent myocardial infarction and 50 healthy subjects were tested for Hageman factor (FXII) coagulant activity and antigen. Among the 103 patients we identified 15 subjects with FXII deficiency (15%), 3 with protein C deficiency (3%) and 3 with protein S deficiency (3%). Combined FXII and protein C, protein S or antithrombin III deficiency was not observed. The 103 patients were devided into subgroups according to the type of thrombotic complication. Among patients with exclusively recurrent venous thromboembolism 8% (p = 0.153) were deficient in FXII. Among patients suffering from recurrent arterial thromboembolism and/or myocardial infarction, the incidence of FXII deficiency was significantly higher (20%, p < 0.003). In 67% of the patients with FXII deficiency a positive family history of thrombosis could be established. In contrast, only 32% of all venous and 28% of all arterial thrombosis patients had a positive family history. We believe that reduced levels of FXII should be considered as a risk factor in the development of thromboembolism. Consequently, more attention should be payed to the measurement of FXII when evaluating thromboembolic risk factors especially in cases of recurrent arterial thromboembolism and/or myocardial infarction.

• References

• 1 Schmaier AH, Silverberg M, Kaplan AP, Colman RW. Contact activation and its abnormalities. Haemostasis and Thrombosis. 2^nd edn Colman RW, Hirsh J, Marder VJ, Salzman EW. Lippincott Company, Philadelphia, PA: 1987: 18-38
  Google Scholar
• 2 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemostas 1987; 13: 50-68
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Ratnoff OD, Busse RJ, Sheron RP. The demise of John Hageman. New Engl J Med 1968; 279: 420-423
  CrossrefPubMedGoogle Scholar
• 4 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factors abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine 1983; 62: 248-255
  CrossrefPubMedGoogle Scholar
• 5 Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-263
  PubMedGoogle Scholar
• 6 Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zürcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency – A study on 74 subjects from 14 Swiss families. Thromb Haemostas 1991; 65: 117-121
  PubMedGoogle Scholar
• 7 Penny WJ, Colvin BT, Brooks N. Myocardial infarction with normal coronary arteries and factor XII deficiency. Br Heart J 1985; 53 (2) 230-234
  CrossrefPubMedGoogle Scholar
• 8 Lodi S, Isa L, Pollini E, Bravo AF, Scalvini A. Defective intrinsic fibrinolytic activity in a patient with severe factor XII-deficiency and myocardial infarction. Scand J Haematol 1984; 33 (1) 80-2
  PubMedGoogle Scholar
• 9 Lodino Jr AV, Luparello FJ. Factor XII deficiency in a man with gout and angioimmunoblastic lymphadenopathy. Arch Intern Med 1984; 144 (7) 1497-1498
  CrossrefPubMedGoogle Scholar
• 10 Hoak JC, Swanson LW, Warner ED, Connor WE. Myocardial infarction associated with severe factor-XII deficiency. Lancet 1966; ii (469) 884-886
  PubMedGoogle Scholar
• 11 Glueck HI, Roehill Jr W. Myocardial infarction in a patient with Hageman (factor XII) defect. Ann Intern Med 1966; 64 (2) 390-396
  CrossrefPubMedGoogle Scholar
• 12 Hellstern P, Koehler M, Schmengler K, Doenecke P, Wenzel E. Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hageman factor deficiency. Acta Haematol 1983; 69 (2) 123-126
  CrossrefPubMedGoogle Scholar
• 13 Thommen D, Buhrfeind E, Felix R, Sulzer I, Furlahn M, Lämmle B. Hämostaseparameter bei 55 Patienten mit venösen und/oder arteriellen Thromboembolien. Schweiz Med Wschr 1989; 119: 493-499
  PubMedGoogle Scholar
• 14 Ferrer MI, Bradley SE, Bull MB, Dolgin M, Ellis K, Enson Y, Escher DJW. et al The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Little, Brown and Company, Boston, MA: 1989: 119 pp
  Google Scholar
• 15 Ratnoff OD, Saito H. The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid. J Lab Clin Med 1982; 100: 248-260
  PubMedGoogle Scholar
• 16 Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemostas 1987; 57: 144-147
  PubMedGoogle Scholar
• 17 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
  CrossrefPubMedGoogle Scholar
• 18 Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. J Clin Chem Clin Biochem 1983; 21: 709-720
  PubMedGoogle Scholar
• 19 Simpson GG, Roe A, Lewontin RC. Quantitative Zoology. Harcourt, Brace & World Inc: New York: 1960. pp 189-191
  Google Scholar
• 20 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
  CrossrefPubMedGoogle Scholar
• 21 Kluft C, Trumpi-Kalshoven MM, Jie AFH, Veldhuyzen-Stolk EC. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. Thromb Haemostas 1979; 41: 756-773
  PubMedGoogle Scholar
• 22 Binnema DJ, Dooijewaard G, van Iersel JJL, Turion PNC, Kluft C. The contact-system dependent plasminogen activator from human plasma: identification and characterization. Thromb Haemostas 1990; 64: 390-397
  PubMedGoogle Scholar
• 23 Levi M, Hack CE, de Boer JP, Brandjes DPM, Büller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. J Clin Invest 1991; 88: 1155-1160
  CrossrefPubMedGoogle Scholar
• 24 Brauer P, Mayer J, Pohl B, Zürrlein P, Keller F. Specificity of confirmatory tests for the diagnosis of a lupus anticoagulant I: mixing studies of the kaolin clotting time. Ann Hematol (Contin Blut), 35^th Annual Meeting of the GTH, Göttingen 1991; A70: 137
  PubMedGoogle Scholar
• 25 Ben-Tal O, Zivelin A, Seligson U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemostas 1989; 61 (1) 50-54
  PubMedGoogle Scholar
• 26 Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516
  CrossrefPubMedGoogle Scholar
• 27 Duckert F. Beeinflussung der Blutgerinnung durch den Diabetes mellitus. Blutgerinnung und Pankreas Tilsner V, Matthias FR. Editiones Roche, Basel: 1986: 155-62
  Google Scholar
• 28 Christe M, Gattlen P, Fritschi J, Lämmle B, Berger W, Marbet GA, Duckert F. The contact phase of blood coagulation in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984; 52: 221-223
  PubMedGoogle Scholar